-+ 0.00%
-+ 0.00%
-+ 0.00%

Guardant Health partners with Nuvalent on companion diagnostics development, commercialization support

PUBT·04/30/2026 12:23:30
Listen to the news
Guardant Health partners with Nuvalent on companion diagnostics development, commercialization support
  • Guardant Health entered a multi-year strategic collaboration with Nuvalent to develop companion diagnostics using Guardant Infinity platform.
  • Deal supports Nuvalent global clinical studies using Guardant tissue and liquid biopsy tests.
  • Parties will evaluate Guardant assays as potential companion diagnostics to support regulatory filings for Nuvalent investigational oncology candidates.
  • Collaboration includes plans to support potential global commercialization of Nuvalent therapies, if approved, alongside Guardant companion diagnostics in major markets.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260430014027) on April 30, 2026, and is solely responsible for the information contained therein.